TERANSMITTAL TO BE USED FORM To be used for all correspondence after initial Number of Pages in This Submission The Transmittal Form	itial filing)	Application Number Filing Date First Named Inventor	09/724,953 June 1, 2000 Schenk, Dale B.	
FORM to be used for all correspondence after initate. tal Number of Pages in This Submission		First Named Inventor	- 	
to be used for all correspondence after ini			Schook Dalo B	
tal Number of Pages in This Submission		A 111 ii	Schenk, Dale B.	
tal Number of Pages in This Submission	16	Group Art Unit	1647	
	16	Examiner Name	Unassigned	
Fee Transmittal Form	10	Attorney Docket Number	15270J-005913US	
Fee Transmittal Form	ENCLO	SURES (check all that apply)		
1		ment Papers Application)	After Allowance Communication to Group	
Fee Attached	Drawing	g(s)	Appeal Communication to Board of Appeals and Interferences	
Amendment / Response	Licensing-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
After Final	and Ac	Routing Slip (PTO/SB/69) companying Petition	Proprietary Information	
Affidavits/declaration(s)		to Convert to a onal Application	Status Letter	
Extension of Time Request	Power of Attorney, Revocation Change of Correspondence Address		Other Enclosure(s) (please identify below):	
Express Abandonment Request	=	al Disclaimer	Return Postcard	
Supplemental IDS Under 37 CFR §1.97 and §1.98 (4 pp.) w/attached PTO/SB/08A & PTO/SB/08B (10 pp.)	CD, Nu	mber of CD(s)		
Certified Copy of Priority Document(s)	Remar	arks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		
Response to Missing Parts/ Incomplete Application				
Response to Missing Parts under 37 CFR 1.52 or 1.53				
		APPLICANT, ATTORNEY, (OR AGENT	
Firm Townsend and Tow	nsend and (Crew LLP		

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, Q.C. 20231 on this date:

September 27, 2001

Typed or printed name	Wanda Alleje			
Signature	Wanda allej.	Date	September 27, 2001	
				_

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3173180 v1

I hereby certify that this correspondence is being deposited with the United

States Postal Service as first class mail in an envelope appress

Assistant Commissioner for Patents Washington, D.C. 20231

THE THE PROPERTY OF

OCT 0 3 **200**

on Lysten sen 27, 200 Aprel

TOWNSEND and TOWNSEND and CREW LLP

By: Waran allge

Attorney Docket No.: 15270J-005913USC Client Reference No.: 209-US-NEW6C3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/724,953

Filed: November 28, 2000

For: PHARMACEUTICAL

COMPOSITIONS AND METHODS FOR

TREATMENT OF AMYLOID

DISEASES

Examiner:

Unassigned

Art Unit:

1647

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references, along with a copy of the International Search Report corresponding to the PCT application, can be found in Application No. 09/585,817, filed June 1, 2000 (Attorney Docket No. 15270J-005910US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Dale B. Schenk

Application No.: 09/724,953

Page 2

The publication identified as Cite No. 144 is a grant application believed to have been submitted by Victor Raso for NIH Grant No. 1 R43 AGI 5746-01 on August 29, 1997. Applicant obtained the grant proposal under the Freedom of Information Act (FOIA). It is believed that the grant proposal would not have been accessible under FOIA before April 2, 1998, but the exact date of public accessibility is not known to Applicant.

Applicants also cite the following commonly owned copending applications directed to related subject matter:

```
09/201,430 filed 11/30/98;
09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00;
09/723,927 filed 11/28/00;
09/724,762 filed 11/28/00;
09/724,102 filed 11/28/00;
09/724,489 filed 11/28/00;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00;
09/724,495 filed 11/27/00;
09/580,015 filed 05/26/00;
09/724,940 filed 11/28/00;
09/724,961 filed 11/28/00;
09/580,018 filed 05/26/00;
09/724,552 filed 11/28/00;
09/723,544 filed 11/28/00;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00;
09/724,288 filed 11/28/00;
09/580,019 filed 05/26/00;
```

Dale B. Schenk

Application No.: 09/724,953

Page 3

```
09/723,765 filed 11/28/00;

09/724,291 filed 11/28/00;

09/204,838 filed 12/03/98;

09/724,921 filed 11/28/00;

09/724,929 filed 11/28/00;

09/724,953 filed 11/28/00;

09/585,817 filed 09/01/01;

09/724,575 filed 11/28/00;

09/724,569 filed 11/28/00;

09/723,766 filed 06/01/00;

09/723,725 filed 11/27/00; and,

09/579,690 filed 05/26/00.
```

Applicants further cite the following commonly owned abandoned applications directed to related subject matter:

```
60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
60/137,010 filed 06/01/99;
60/137,047 filed 06/01/99; and,
60/136,655 filed 05/28/99.
```

Applicants point out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

```
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838, filed 12/3/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.
```

Dale B. Schenk

Application No.: 09/724,953

Page 4

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom. As provided for by 37 CFR §§ 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Rosemarie L. Celli Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

RLC

PA 3172939 v1